Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826486 · ClinicalTrials.gov registry record · Phase 2
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
A Phase 2 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02826486: Completed Phase 2 study, sponsored by BioLineRx.
NCT02826486 is a Phase 2 study that has completed, run by BioLineRx. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02826486, a Phase 2 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL-8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.
Interventions
- DRUG Pembrolizumab
- DRUG Chemotherapy
- DRUG BL-8040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-09 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02826486
The ClinicalTrials.gov registry entry for NCT02826486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02826486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02826486 about?
NCT02826486 is a clinical study titled "Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients". This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL-8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma.
What is the current status of trial NCT02826486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-09. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT02826486?
The interventions under investigation include: Pembrolizumab (DRUG), Chemotherapy (DRUG), BL-8040 (DRUG).
Who is sponsoring clinical trial NCT02826486?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.